{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:37:57Z","timestamp":1781534277255,"version":"3.54.5"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010409","name":"Children's Investment Fund Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008223","name":"Association of Academic Physiatrists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012297","name":"Society of Family Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012297","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012756","name":"Lalor Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005295","name":"American Academy of Pediatrics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005295","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["FHI360"],"award-info":[{"award-number":["FHI360"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.contraception.2025.110862","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T11:46:22Z","timestamp":1741002382000},"page":"110862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Uses of ulipristal acetate beyond emergency contraception: A narrative review"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9867-1678","authenticated-orcid":false,"given":"Ashley M.","family":"Ebersole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Liberty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Edelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Lyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Cleland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.contraception.2025.110862_bib1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.contraception.2013.05.010","article-title":"Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens","volume":"88","author":"Brache","year":"2013","journal-title":"Contraception"},{"issue":"2 Pt 1","key":"10.1016\/j.contraception.2025.110862_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/AOG.0b013e3181c8e2aa","article-title":"Ulipristal acetate taken 48-120\u2009h after intercourse for emergency contraception","volume":"115","author":"Fine","year":"2010","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.contraception.2025.110862_bib3","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1210\/endo.140.3.6581","article-title":"The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestins","volume":"140","author":"Wagner","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.contraception.2025.110862_bib4","unstructured":"Innovation VH. Covidence. Melbourne, Australia. https:\/\/www.covidence.org\/."},{"issue":"17","key":"10.1016\/j.contraception.2025.110862_bib5","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1001\/jama.2024.0447","article-title":"Uterine fibroids","volume":"331","author":"Marsh","year":"2024","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.contraception.2025.110862_bib6","article-title":"Efficacy of ulipristal acetate in women with fibroid induced menorrhagia: a systematic review and meta-analysis","volume":"50","author":"Kounidas","year":"2021","journal-title":"J\u00a0Gynecol\u00a0Obstet\u00a0Hum\u00a0Reprod"},{"issue":"2","key":"10.1016\/j.contraception.2025.110862_bib7","first-page":"141","article-title":"A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids","volume":"146","author":"Ghonim","year":"2019","journal-title":"Int\u00a0J\u00a0Gynecol\u00a0Obstet"},{"issue":"2","key":"10.1016\/j.contraception.2025.110862_bib8","first-page":"91","article-title":"Ulipristal acetate for uterine fibroids: a systematic review and meta-analysis","volume":"32","author":"Kalampokas","year":"2016","journal-title":"Gynecol\u00a0Endocrinol"},{"issue":"10","key":"10.1016\/j.contraception.2025.110862_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186158","article-title":"Pre-treatment with GnRHa or ulipristal acetate prior to laparoscopic and laparotomic myomectomy: a systematic review and meta-analysis","volume":"12","author":"De Milliano","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.contraception.2025.110862_bib10","first-page":"1121","article-title":"What happens after randomised controlled trials? Uterine fibroids and ulipristal acetate: systematic review and meta-analysis of \"real-world\" data","volume":"303","author":"Shah","year":"2021","journal-title":"Arch\u00a0Gynecol\u00a0Obstet"},{"issue":"2","key":"10.1016\/j.contraception.2025.110862_bib11","first-page":"127","article-title":"Ulipristal acetate before hysteroscopic myomectomy: a systematic review","volume":"75","author":"Vitale","year":"2020","journal-title":"Obstet\u00a0Gynecol\u00a0Surv"},{"key":"10.1016\/j.contraception.2025.110862_bib12","first-page":"43","article-title":"Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study","volume":"205","author":"Ferrero","year":"2016","journal-title":"Eur\u00a0J\u00a0Obstet\u00a0Gynecol\u00a0Reprod\u00a0Biol"},{"issue":"8","key":"10.1016\/j.contraception.2025.110862_bib13","first-page":"1066","article-title":"Pregnancy outcomes following ulipristal acetate for uterine fibroids: a systematic review","volume":"40","author":"De Gasperis-Brigante","year":"2018","journal-title":"J\u00a0Obstet\u00a0Gynaecol\u00a0Can"},{"key":"10.1016\/j.contraception.2025.110862_bib14","first-page":"551","article-title":"The course and outcomes of pregnancy in women with uterine fibroids treated with therapy has ulipristal acetate","volume":"45","author":"Ignatko","year":"2017","journal-title":"J\u00a0Perinat\u00a0Med"},{"issue":"3","key":"10.1016\/j.contraception.2025.110862_bib15","first-page":"199","article-title":"Effect of ulipristal acetate on gene expression profile in endometrial cells in culture and in vivo upon post-ovulatory administration in fertile women","volume":"27","author":"Jim\u00e9nez Guerrero","year":"2022","journal-title":"Eur\u00a0J\u00a0Contracept\u00a0Reprod\u00a0Health Care"},{"issue":"6","key":"10.1016\/j.contraception.2025.110862_bib16","first-page":"2035","article-title":"Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914","volume":"93","author":"Stratton","year":"2010","journal-title":"Fertil\u00a0Steril"},{"issue":"10","key":"10.1016\/j.contraception.2025.110862_bib17","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1093\/humrep\/deu210","article-title":"Ulipristal acetate resembles mifepristone in modulating human fallopian tube function","volume":"29","author":"Li","year":"2014","journal-title":"Hum Reprod"},{"issue":"9","key":"10.1016\/j.contraception.2025.110862_bib18","first-page":"3582","article-title":"Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial","volume":"92","author":"Chabbert-Buffet","year":"2007","journal-title":"J\u00a0Clin\u00a0Endocrinol\u00a0Metab"},{"key":"10.1016\/j.contraception.2025.110862_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.contraception.2022.04.002","article-title":"Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84 day ulipristal acetate regimens","volume":"112","author":"Westhoff","year":"2022","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.contraception.2025.110862_bib20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/modpathol.2008.19","article-title":"The spectrum of endometrial pathology induced by progesterone receptor modulators","volume":"21","author":"Mutter","year":"2008","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.contraception.2025.110862_bib21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.contraception.2014.08.006","article-title":"A randomized study on pharmacodynamic effects of vaginal rings delivering the progesterone receptor modulator ulipristal acetate: research for a novel estrogen-free, method of contraception","volume":"90","author":"Huang","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.110862_bib22","unstructured":"NCT. A study to evaluate the effect of a contraceptive vaginal ring delivering ulipristal acetate combined with a single or repeated levonorgestrel on inhibition of ovulation, endometrial changes and bleeding patterns in normal cycling women. https:\/\/clinicaltrialsgov\/show\/NCT02451826; 2015."},{"issue":"3","key":"10.1016\/j.contraception.2025.110862_bib23","first-page":"1419","article-title":"In vitro effect of ulipristal acetate on human sperm parameters and function","volume":"32","author":"Sha","year":"2019","journal-title":"Pak J\u00a0Pharm\u00a0Sci"},{"issue":"6","key":"10.1016\/j.contraception.2025.110862_bib24","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.2047-2927.2014.00261.x","article-title":"An in vitro study of the effect of mifepristone and ulipristal acetate on human sperm functions","volume":"2","author":"Ko","year":"2014","journal-title":"Andrology"},{"issue":"1","key":"10.1016\/j.contraception.2025.110862_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/rmb2.12598","article-title":"Oxidative stress affects sperm health and fertility-time to apply facts learned at the bench to help the patient: lessons for busy clinicians","volume":"23","author":"Sengupta","year":"2024","journal-title":"Reprod Med Biol"},{"issue":"5","key":"10.1016\/j.contraception.2025.110862_bib26","first-page":"355","article-title":"Effects of ulipristal acetate on sperm DNA fragmentation during in vitro incubation","volume":"18","author":"Munuce","year":"2013","journal-title":"Eur\u00a0J\u00a0Contracept\u00a0Reprod\u00a0Health Care"},{"issue":"5","key":"10.1016\/j.contraception.2025.110862_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.contraception.2011.01.021","article-title":"Contraceptive failure in the United States","volume":"83","author":"Trussell","year":"2011","journal-title":"Contraception"},{"issue":"6","key":"10.1016\/j.contraception.2025.110862_bib28","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/ajo.12534","article-title":"User characteristics, experiences and continuation rates of copper intrauterine device use in a cohort of Australian women","volume":"56","author":"Bateson","year":"2016","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"4","key":"10.1016\/j.contraception.2025.110862_bib29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.contraception.2021.06.010","article-title":"Pharmacodynamics and pharmacokinetics of a copper intrauterine contraceptive system releasing ulipristal acetate: a randomized proof-of-concept study","volume":"104","author":"Brache","year":"2021","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.contraception.2025.110862_bib30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.contraception.2016.02.030","article-title":"Twelve-month discontinuation of etonogestrel implant in an outpatient pediatric setting","volume":"94","author":"Berlan","year":"2016","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.contraception.2025.110862_bib31","first-page":"888","article-title":"Ulipristal acetate for unscheduled bleeding in etonogestrel implant users a randomized controlled trial","volume":"132","author":"Zigler","year":"2018","journal-title":"Obstet\u00a0Gynecol"},{"issue":"1","key":"10.1016\/j.contraception.2025.110862_bib32","first-page":"10","article-title":"A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system","volume":"149","author":"Fava","year":"2020","journal-title":"Int\u00a0J\u00a0Gynecol\u00a0Obstet"},{"issue":"2","key":"10.1016\/j.contraception.2025.110862_bib33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/humrep\/dep377","article-title":"Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding","volume":"25","author":"Warner","year":"2010","journal-title":"Hum Reprod"},{"issue":"5","key":"10.1016\/j.contraception.2025.110862_bib34","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/AOG.0000000000005137","article-title":"Heavy menstrual bleeding treatment with a levonorgestrel 52-mg intrauterine device","volume":"141","author":"Creinin","year":"2023","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2025.110862_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101995","article-title":"Ulipristal acetate versus levonorgestrel-releasing intrauterine system for heavy menstrual bleeding (UCON): a randomised controlled phase III trial","volume":"60","author":"Whitaker","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"5","key":"10.1016\/j.contraception.2025.110862_bib36","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/01443615.2017.1287687","article-title":"An observation study of the clinical evaluation of symptom relief and side effects associated with taking ulipristal acetate (esmya) including its effect on pre-menstrual syndrome","volume":"37","author":"Chen","year":"2017","journal-title":"J Obstet Gynaecol"},{"issue":"7","key":"10.1016\/j.contraception.2025.110862_bib37","first-page":"S186","article-title":"Ulipristal acetate and pelvic pain","volume":"24","author":"Scattolon","year":"2017","journal-title":"J\u00a0Minim\u00a0Invasive Gynecol"},{"issue":"7","key":"10.1016\/j.contraception.2025.110862_bib38","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1016\/j.jmig.2019.09.192","article-title":"Ulipristal acetate for adenomyosis: a multicenter randomized trial","volume":"26","author":"Fernandez","year":"2019","journal-title":"J\u00a0Minim Invasive Gynecol"},{"issue":"1","key":"10.1016\/j.contraception.2025.110862_bib39","article-title":"Ulipristal acetate use in adenomyosis: a randomized controlled trial","volume":"50","author":"Capmas","year":"2021","journal-title":"J\u00a0Gynecol\u00a0Obstet\u00a0Hum\u00a0Reprod"},{"issue":"3","key":"10.1016\/j.contraception.2025.110862_bib40","first-page":"e281","article-title":"Changes in adenomyosis after treatment with ulipristal acetate","volume":"106","author":"Ferrero","year":"2016","journal-title":"Fertil\u00a0Steril"},{"issue":"1","key":"10.1016\/j.contraception.2025.110862_bib41","first-page":"260","article-title":"Effects of ulipristal acetate on reactive oxygen species and proinflammatory cytokine release by epithelial and stromal cells from human endometrium and endometriosis","volume":"31","author":"Reis","year":"2024","journal-title":"Reprod\u00a0Sci"},{"issue":"3","key":"10.1016\/j.contraception.2025.110862_bib42","first-page":"531","article-title":"Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium","volume":"32","author":"Whitaker","year":"2017","journal-title":"Hum Reprod"},{"issue":"5","key":"10.1016\/j.contraception.2025.110862_bib43","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/AOG.0000000000004754","article-title":"Cervical preparation using ulipristal acetate with adjunct misoprostol in second-trimester surgical abortions","volume":"139","author":"Peterson","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"1 Pt 1","key":"10.1016\/j.contraception.2025.110862_bib44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0002-9378(97)80024-5","article-title":"Proliferation of breast epithelial cells in healthy women during the menstrual cycle","volume":"176","author":"Soderqvist","year":"1997","journal-title":"Am J Obstet Gynecol"},{"issue":"29","key":"10.1016\/j.contraception.2025.110862_bib45","doi-asserted-by":"crossref","first-page":"45317","DOI":"10.18632\/oncotarget.9638","article-title":"Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations","volume":"7","author":"Communal","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.contraception.2025.110862_bib46","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.canlet.2021.07.034","article-title":"Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes","volume":"520","author":"Lee","year":"2021","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.contraception.2025.110862_bib47","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13073-022-01063-5","article-title":"Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women","volume":"14","author":"Bartlett","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.contraception.2025.110862_bib48","series-title":"Abstract P1-10-01: results from the breast cancer - anti progestin prevention study 1 (BC-APPS1) trial - a novel approach in breast cancer prevention San Antonio Breast Cancer Symposium","author":"Howell","year":"2021"},{"issue":"2","key":"10.1016\/j.contraception.2025.110862_bib49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10549-021-06503-1","article-title":"The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation","volume":"192","author":"Westhoff","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.contraception.2025.110862_bib50","article-title":"Low dose of CDB-2914 and CDB-4124 efficiently inhibit the growth of T47D spheroid induced by pre-menopausal and post-menopausal concentrations of estrogen and progesterone","volume":"75","author":"Lee","year":"2015","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.contraception.2025.110862_bib51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12672-016-0255-4","article-title":"Anti-tumoral effects of anti-progestins in a patient-derived breast cancer xenograft model","volume":"7","author":"Esber","year":"2016","journal-title":"Horm Cancer"},{"key":"10.1016\/j.contraception.2025.110862_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114607","article-title":"Z-Endoxifen prevents aggressive mammary cancers in mice by inhibiting cell proliferation and creating a tumor suppressive microenvironment","volume":"162","author":"Lee","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.contraception.2025.110862_bib53","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10143-018-0953-1","article-title":"Reproductive epidemiology of glial tumors may reveal novel treatments: high-dose progestins or progesterone antagonists as endocrino-immune modifiers against glioma","volume":"42","author":"Altinoz","year":"2019","journal-title":"Neurosurg Rev"},{"issue":"4","key":"10.1016\/j.contraception.2025.110862_bib54","first-page":"468","article-title":"Ulipristal-temozolomide-hydroxyurea combination for glioblastoma: in-vitro studies","volume":"68","author":"Altinoz","year":"2024","journal-title":"J\u00a0Neurosurg\u00a0Sci"},{"issue":"14","key":"10.1016\/j.contraception.2025.110862_bib55","article-title":"Anti-tumor effect of selective progesterone receptor modulator (ulipristal acetate) on endometrial cancer cell lines","volume":"76","author":"Lee","year":"2016","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.contraception.2025.110862_bib56","first-page":"1543","article-title":"Ulipristal acetate induces apoptosis and senescence via activation of oncostatin M in endometrial cancer cells","volume":"46","author":"Kanda","year":"2020","journal-title":"J\u00a0Obstet\u00a0Gynaecol\u00a0Res"},{"issue":"1","key":"10.1016\/j.contraception.2025.110862_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e08696","article-title":"Ulipristal acetate simultaneously provokes antiproliferative and proinflammatory responses in endometrial cancer cells","volume":"8","author":"Kanda","year":"2022","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.contraception.2025.110862_bib58","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400209","article-title":"A proof-of-concept study of ulipristal acetate for early medication abortion","volume":"4","author":"Winikoff","year":"2025","journal-title":"NEJM Evid"},{"key":"10.1016\/j.contraception.2025.110862_bib59","unstructured":"European Medicines Agency: Ulipristal acetate 5mg medicinal products \u2013 referral https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/ulipristal-acetate-5mg-medicinal-products, Novembre 2020."},{"issue":"12","key":"10.1016\/j.contraception.2025.110862_bib60","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s40264-020-00960-1","article-title":"An evaluation of postmarketing reports of serious idiosyncratic liver injury associated with ulipristal acetate for the treatment of uterine fibroids","volume":"43","author":"Kang","year":"2020","journal-title":"Drug Saf"},{"issue":"12","key":"10.1016\/j.contraception.2025.110862_bib61","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/14740338.2018.1550070","article-title":"Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program","volume":"17","author":"Donnez","year":"2018","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"10.1016\/j.contraception.2025.110862_bib62","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.cgh.2022.12.040","article-title":"The evolving profile of idiosyncratic drug-induced liver injury","volume":"21","author":"Fontana","year":"2023","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782425000538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782425000538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:15:34Z","timestamp":1777641334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782425000538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":62,"alternative-id":["S0010782425000538"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2025.110862","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uses of ulipristal acetate beyond emergency contraception: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2025.110862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110862"}}